<DOC>
	<DOCNO>NCT02023905</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , everolimus ( RAD001 , also know Afinitor® ) alone temozolomide patient patient 's low-grade glioma . Everolimus investigate anticancer agent base potential prevent tumor cell grow multiplying . Specifically , protein call mTOR think help many tumor grow , everolimus block effect mTOR . Temozolomide also anticancer agent prevents tumor cell grow multiplying . About 159 people total take part study . Patients assign one three treatment group depend result test do tumor . Each group 53 patient . 2 group receive treatment everolimus alone , third group receive treatment everolimus temozolomide . In study , patient assign one 3 treatment arm base two characteristic tumor , call `` 1p/19q '' ( test tumor chromosome ) `` p-PRAS40 '' ( test pathway tumor call mTOR ) . If patient 's tumor 1p/19q intact p-PRAS40 positive , patient assign Treatment Arm 1 , patient receive everolimus alone . If patient 's tumor 1p/19q intact p-PRAS40 negative , patient assign Treatment Arm 2 patient receive everolimus temozolomide . If patient 's tumor 1p/19q co-deleted , regardless p-PRAS40 result , patient assign Treatment Arm 3 , patient receive everolimus alone .</brief_summary>
	<brief_title>Everolimus With Without Temozolomide Adult Low Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Age ≥ 18 year KPS ≥ 60 Adequate bone marrow function show : ANC ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hb ≥ 9.0 g/dL ; Adequate liver function show : Total serum bilirubin ≤ 2.0 mg/dL , ALT AST ≤ 2.5x ULN , INR ≤ 2 ; Adequate renal function : serum creatinine ≤1.5 x ULN ; Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fast triglyceride ≤ 2.5x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication confirm reduction lab value within eligibility parameter ; Signed informed consent prior screen procedure Histologically proven supratentorial lowgrade glioma initial diagnosis ; pathology must review UCSF neuropathology . Eligible lowgrade glioma include : astrocytoma , oligodendroglioma mixed oligoastrocytoma . Pilocytic astrocytomas exclude . Results 1p/19q chromosomal status pPRAS40 test must available permit treatment selection . Evaluable disease Must begin treatment within 120 day surgical procedure No prior tumor treatment except surgery diagnosis , must adequately recover surgery Known intolerance hypersensitivity everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) temozolomide Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral everolimus temozolomide Uncontrolled diabetes mellitus define HbA1c &gt; 8.0 % despite adequate therapy . Patients known history impair fast glucose diabetes mellitus ( DM ) may include , however blood glucose antidiabetic treatment must monitor closely throughout trial adjust necessary ; Any severe and/or uncontrolled medical condition : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior start everolimus , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease ; symptomatic congestive heart failure New York heart Association Class III IV ; active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , decompensated liver disease , chronic hepatitis ( i.e . quantifiable HBVDNA and/or positive HbsAg , quantifiable HCVRNA ) ; know severely impaired lung function ( spirometry DLCO 50 % less normal O2 saturation 88 % less rest room air ) ; active , bleeding diathesis ; Chronic treatment corticosteroid immunosuppressive agent . Topical inhale corticosteroid allow , treatment low dose Decadron ( ≤ 3mg daily ) allow ; Known history HIV seropositivity ; Positive serological test result hepatitis B Positive serological test result hepatitis C Recipients live attenuate vaccine within 1 week start treatment study . Avoid close contact others receive live attenuate vaccine . Examples live attenuate vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella TY21a typhoid vaccine ; History another primary malignancy , exception : nonmelanoma skin cancer , carcinoma situ cervix , uterus , breast , unless patient disease free ≥ 3 year ; History noncompliance medical regimen consider potentially unreliable able complete entire study ; Currently part participate clinical investigation investigational therapeutic drug within 1 month prior dose ; Pregnant nursing ( lactate ) woman ; Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , willing use adequate method contraception study 8 week end treatment . Women consider postmenopausal childbearing potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior randomization . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider childbearing potential . Male patient whose sexual partner ( ) WOCBP willing use adequate contraception , study 8 week end treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>